孤儿药-话题@MedSci

#孤儿药#

9篇内容 | 2908人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2280848, encodeId=88a4228084830, content=<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a> <a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a> <a href='/topic/show?id=d9ba5402266' target=_blank style='color:#2F92EE;'>#成本效果分析#</a> <a href='/topic/show?id=8e1b3663336' target=_blank style='color:#2F92EE;'>#卫生技术评估#</a>, objectTitle=PharmacoEconomics：等待 5 年才确诊，95% 无特效药！罕见病患者困境背后，孤儿药评估体系如何破局？, objectType=article, longId=896370, objectId=51028963e067, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/102373157-95011716.1910x1000.jpg, objectUrl=/article/show_article.do?id=51028963e067, replyNumber=0, likeNumber=27, createdTime=2025-09-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=51028963e067, moduleTitle=PharmacoEconomics：等待 5 年才确诊，95% 无特效药！罕见病患者困境背后，孤儿药评估体系如何破局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51028963e067)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1241284, encodeId=1f791241284fe, content=<a href='/topic/show?id=727939160d8' target=_blank style='color:#2F92EE;'>#君实生物#</a><a href='/topic/show?id=333a6802212' target=_blank style='color:#2F92EE;'>#特瑞普利单抗#</a>治疗<a href='/topic/show?id=c3f910342343' target=_blank style='color:#2F92EE;'>#鼻咽癌#</a>再获欧盟<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>资格认定, objectTitle=君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定, objectType=article, longId=737113, objectId=f35ee3711364, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220826/1661510531099_5604654.png, objectUrl=/article/show_article.do?id=f35ee3711364, replyNumber=0, likeNumber=182, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f35ee3711364, moduleTitle=君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f35ee3711364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241285, encodeId=f1e6124128507, content=<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a><a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a><a href='/topic/show?id=1d4424289be' target=_blank style='color:#2F92EE;'>#亚盛医药#</a>, objectTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, objectType=article, longId=200423, objectId=5feb2004238f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202098/1599495157744_2119349.jpg, objectUrl=/article/show_article.do?id=5feb2004238f, replyNumber=0, likeNumber=173, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5feb2004238f, moduleTitle=亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5feb2004238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241286, encodeId=6a6512412861f, content=<a href='/topic/show?id=36a59e3106' target=_blank style='color:#2F92EE;'>#ilixadencel#</a>治疗<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝细胞癌#</a>（HCC）的<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>, objectTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, objectType=article, longId=205226, objectId=9130205226b7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202112/1609563583413_5295902.jpeg, objectUrl=/article/show_article.do?id=9130205226b7, replyNumber=0, likeNumber=171, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9130205226b7, moduleTitle=FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9130205226b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241287, encodeId=655d124128e36, content=<a href='/topic/show?id=c6ec1046085e' target=_blank style='color:#2F92EE;'>#博生吉医药#</a><a href='/topic/show?id=8c1510460960' target=_blank style='color:#2F92EE;'>#CD7#</a>靶向<a href='/topic/show?id=4e2640e283' target=_blank style='color:#2F92EE;'>#CAR-T细胞#</a>注射液获得美国FDA<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>资格认定, objectTitle=博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定, objectType=article, longId=220150, objectId=4aba220150d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20211102/c7e6195927c44dea86dcfcf86268371c.jpg, objectUrl=/article/show_article.do?id=4aba220150d9, replyNumber=0, likeNumber=154, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba220150d9, moduleTitle=博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba220150d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241288, encodeId=ce86124128876, content=<a href='/topic/show?id=41e019635b' target=_blank style='color:#2F92EE;'>#ADC药物#</a>获得FDA<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>, objectTitle=治疗胃癌！石药ADC药物获得FDA孤儿药资格认定, objectType=article, longId=204115, objectId=d7c4204115f7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020124/1607011804933_2119349.jpg, objectUrl=/article/show_article.do?id=d7c4204115f7, replyNumber=0, likeNumber=151, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7c4204115f7, moduleTitle=治疗胃癌！石药ADC药物获得FDA孤儿药资格认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7c4204115f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1241276, encodeId=bb0112412e6be, content=<a href='/topic/show?id=5dd28335eea' target=_blank style='color:#2F92EE;'>#胃肠道间质瘤#</a><a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>, objectTitle=胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”, objectType=article, longId=207384, objectId=922f20e38487, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021220/1613828414568_5295902.jpeg, objectUrl=/article/show_article.do?id=922f20e38487, replyNumber=0, likeNumber=157, createdTime=2022-08-27, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=922f20e38487, moduleTitle=胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=922f20e38487)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=914996, encodeId=0ce2914996bd, content=<a href='/topic/show?id=3123104096da' target=_blank style='color:#2F92EE;'>#MC-1#</a>&<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>, objectTitle=FDA授予MC-1治疗磷酸吡哆醇(胺)氧化酶(PNPO)缺乏症的“孤儿药称号”, objectType=article, longId=205513, objectId=71f620551356, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202118/1610107571037_5295902.jpeg, objectUrl=/article/show_article.do?id=71f620551356, replyNumber=0, likeNumber=241, createdTime=2021-01-09, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71f620551356, moduleTitle=FDA授予MC-1治疗磷酸吡哆醇(胺)氧化酶(PNPO)缺乏症的“孤儿药称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71f620551356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=884679, encodeId=5b538846e98f, content=<a href='/topic/show?id=b11868811f1' target=_blank style='color:#2F92EE;'>#甘李药业#</a>宣布<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>授予其细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂GLR2007<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>资格，用于治疗包括<a href='/topic/show?id=01858406438' target=_blank style='color:#2F92EE;'>#胶质母细胞瘤#</a>（GBM）在内的<a href='/topic/show?id=8d2452942c2' target=_blank style='color:#2F92EE;'>#恶性胶质瘤#</a>，有些迷惑了。CDK4/6不是用于<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>，<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>的吗？, objectTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, objectType=article, longId=200588, objectId=285f20058863, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020911/1599837648162_2119349.jpg, objectUrl=/article/show_article.do?id=285f20058863, replyNumber=0, likeNumber=401, createdTime=2020-09-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285f20058863, moduleTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285f20058863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=880633, encodeId=1b898806335f, content=AXS-12已获得美国食品和药物管理局（FDA）的突破性疗法称号和<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>称号，用于治疗<a href='/topic/show?id=cd45402219c' target=_blank style='color:#2F92EE;'>#嗜睡症#</a>。, objectTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, objectType=article, longId=200039, objectId=e77f200039b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020829/1598691133835_5295902.jpeg, objectUrl=/article/show_article.do?id=e77f200039b3, replyNumber=1, likeNumber=315, createdTime=2020-08-29, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77f200039b3, moduleTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77f200039b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

孤儿药

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#孤儿药# #罕见病# #成本效果分析# #卫生技术评估#

PharmacoEconomics：等待 5 年才确诊，95% 无特效药！罕见病患者困境背后，孤儿药评估体系如何破局？

2025-09-11发表于上海

循证小兵 (审核中...)

前往app查看评论内容

#君实生物##特瑞普利单抗#治疗#鼻咽癌#再获欧盟#孤儿药#资格认定

君实生物特瑞普利单抗治疗鼻咽癌再获欧盟孤儿药资格认定

2022-08-27

循证小兵 (审核中...)

前往app查看评论内容

#慢性淋巴细胞白血病##孤儿药##亚盛医药#

亚盛医药Bcl-2抑制剂再获FDA孤儿药资格认定，治疗慢性淋巴细胞白血病

2022-08-27

循证小兵 (审核中...)

前往app查看评论内容

#ilixadencel#治疗#肝细胞癌#（HCC）的#孤儿药#

FDA授予Ilixadencel治疗肝细胞癌（HCC）的“孤儿药称号”

2022-08-27

循证小兵 (审核中...)

前往app查看评论内容

#博生吉医药##CD7#靶向#CAR-T细胞#注射液获得美国FDA#孤儿药#资格认定

博生吉医药CD7靶向CAR-T细胞注射液获得美国FDA孤儿药资格认定

2022-08-27

循证小兵 (审核中...)

前往app查看评论内容

#ADC药物#获得FDA#孤儿药#

治疗胃癌！石药ADC药物获得FDA孤儿药资格认定

2022-08-27

循证小兵 (审核中...)

前往app查看评论内容

#胃肠道间质瘤##孤儿药#

胃肠道间质瘤（GIST）的治疗或迎新突破，EMA授予Ilixadencel“孤儿药资格”

2022-08-27

zb1235672 (审核中...)

前往app查看评论内容

#MC-1#&#孤儿药#

FDA授予MC-1治疗磷酸吡哆醇(胺)氧化酶(PNPO)缺乏症的“孤儿药称号”

2021-01-09

lovetcm (审核中...)

前往app查看评论内容

#甘李药业#宣布#FDA#授予其细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂GLR2007#孤儿药#资格，用于治疗包括#胶质母细胞瘤#（GBM）在内的#恶性胶质瘤#，有些迷惑了。CDK4/6不是用于#乳腺癌#，#卵巢癌#的吗？

甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤

2020-09-12

lovetcm (审核中...)

前往app查看评论内容

AXS-12已获得美国食品和药物管理局（FDA）的突破性疗法称号和#孤儿药#称号，用于治疗#嗜睡症#。

SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓

2020-08-29

科室
- - 订阅+
  - 更多科室
工具
服务